此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

来那度胺和 Dinutuximab 联合或不联合异维甲酸治疗难治性或复发性神经母细胞瘤的年轻患者

2026年11月10日 更新者:National Cancer Institute (NCI)

来那度胺和抗 GD2 单克隆抗体 Ch14.18 +/- 异维甲酸治疗难治性/复发性神经母细胞瘤患者的 I 期研究

This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together with dinutuximab therapy may kill more tumor cells.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of lenalidomide in combination with fixed doses of dinutuximab (ch14.18) and isotretinoin given to children with refractory or recurrent neuroblastoma.

II. To define the toxicities of lenalidomide administered in combination with ch14.18 and isotretinoin.

III. To describe the differences in immune function modulation between "low" versus "high" dose lenalidomide given with ch14.18 and isotretinoin.

SECONDARY OBJECTIVES:

I. To determine the pharmacokinetics of lenalidomide given in this combination regimen.

II. To determine the steady state pharmacokinetics of isotretinoin (day 28, course one) given in combination with lenalidomide.

III. To measure peak and trough levels of ch14.18 in patients receiving lenalidomide and to compare to historical controls of patients receiving ch14.18 in combination with interleukin 2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

IV. To describe the immunological effects of lenalidomide (T cells, natural killer [NK] cells, monocytes, cytokines, chemokines) within this three drug regimen.

V. To define the incidence and titers of human anti-chimeric antibody (HACA) on this regimen.

VI. To describe, within the context of a phase I study, the response rate to lenalidomide combined with ch14.18 and isotretinoin in patients with recurrent/refractory neuroblastoma.

VII. To summarize, within the context of a phase I study, the event-free survival of patients with recurrent/refractory neuroblastoma or in complete response (CR) after progressing, and who are treated with lenalidomide combined with ch14.18 and isotretinoin.

VIII. To determine, within the context of a phase I study, if killer-cell immunoglobulin-like receptor (KIR) receptor-ligand mismatch or specific Fc gamma receptor (Fc gamma R) alleles are associated with anti-tumor response.

IX. To quantify neuroblastoma tumor cell "load" using a 5-gene TaqMan Low Density Array (TLDA) assay in peripheral blood at study entry, following, with each disease evaluation and at end of therapy and bone marrow at study entry, with each response evaluation when bone marrow is sampled, and at end of therapy.

X. To compare the toxicities of this regimen with the historical toxicity data from the Children's Oncology Group (COG) ANBL0032 and ANBL0931 studies of ch14.18 with IL-2, GM-CSF and isotretinoin.

XI. To describe the tolerability and ability to give full doses of ch14.18 and lenalidomide over extended periods of time, i.e. in courses 6-12.

OUTLINE: This is a dose-escalation study of lenalidomide.

Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21, dinutuximab intravenously (IV) over 10 hours on days 8-11, and isotretinoin PO twice daily (BID) on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

研究类型

介入性

注册 (实际的)

27

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5G 1X8
        • Hospital for Sick Children
    • California
      • Los Angeles、California、美国、90027
        • Children's Hospital Los Angeles
      • Palo Alto、California、美国、94304
        • Lucile Packard Children's Hospital Stanford University
      • San Francisco、California、美国、94143
        • UCSF Medical Center-Parnassus
    • Colorado
      • Aurora、Colorado、美国、80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta、Georgia、美国、30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
    • Illinois
      • Chicago、Illinois、美国、60637
        • University of Chicago Comer Children's Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • Dana-Farber Cancer Institute
      • Boston、Massachusetts、美国、02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • C S Mott Children's Hospital
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • UNC Lineberger Comprehensive Cancer Center
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • Cincinnati Children's Hospital Medical Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Children's Hospital of Philadelphia
    • Texas
      • Fort Worth、Texas、美国、76104
        • Cook Children's Medical Center
    • Washington
      • Seattle、Washington、美国、98105
        • Seattle Children's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 21年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines

  • Patients must have high-risk neuroblastoma

  • Patients must have at least ONE of the following:

    • Recurrent/progressive disease at any time prior to enrollment - regardless of response to frontline therapy
    • Refractory disease: persistent sites of disease (after less than a partial response to frontline therapy, following a minimum of 4 cycles of induction therapy) AND patient has never had a relapse/progression
    • Persistent disease: persistent disease after achieving at least a partial response to frontline therapy after a minimum of 4 cycles of induction therapy and patient has never had a relapse/progression
  • Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below):

    • Bone disease

      • At least one metaiodobenzylguanidine (MIBG) avid bone site or diffuse MIBG uptake

        • For recurrent/progressive or refractory disease a biopsy is not required regardless of number of MIBG avid lesions
        • For persistent disease, if patient has only 1 or 2 MIBG avid lesions OR a Curie score of 1-2, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one site present at the time of enrollment (bone marrow, bone, or soft tissue) is required to be obtained at any time point prior to enrollment and two weeks subsequent to most recent prior therapy; if a patient has 3 or more MIBG avid lesions OR a Curie score of >= 3 then no biopsy is required for eligibility
      • If a tumor is known to be MIBG non-avid, then a patient must have at least one fludeoxyglucose (FDG)-positron emission tomography (PET) avid bone site present at the time of enrollment with biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma obtained at any time prior to enrollment and two weeks subsequent to most recent prior therapy

    • Any amount of neuroblastoma tumor cells in the bone marrow based on routine morphology (with or without immunocytochemistry) in at least one sample from bilateral aspirates and biopsies

    • At least one soft tissue lesion that meets the criteria for a TARGET lesion as defined by:

      • SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter >= 10 mm, or for lymph nodes >= 15 mm on short axis; lesions meeting size criteria will be considered measurable

      • In addition to size, a lesion needs to meet ONE of the following criteria:

        • MIBG avid; for patients with persistent disease only: if a patient has only 1 or 2 MIBG avid lesions OR a Curie score of 1-2, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one site present at time of enrollment (either bone marrow, bone and/or soft tissue) is required to be obtained at any time point prior to enrollment and at least two weeks subsequent to most recent prior therapy; if a patient has 3 or more MIBG avid lesions OR a Curie score of >= 3 then no biopsy is required for eligibility
        • FDG-PET avid (only if tumor is known to be MIBG non-avid); these patients must have had a biopsy confirming neuroblastoma and/or ganglioneuroblastoma in at least one FDG-PET avid site present at the time of enrollment done prior to enrollment and at least two weeks subsequent to the most recent prior therapy
        • Non-avid lesion (both MIBG and FDG-PET non-avid); these patients must have had a biopsy confirming neuroblastoma and/or ganglioneuroblastoma in at least one non-avid lesion present at the time of enrollment done prior to enrollment and at least two weeks subsequent to the most recent prior therapy
  • Patients with prior progressive disease who do not meet criteria above, are eligible as long as they have not been off treatment for > 3 months prior to enrollment on NANT 2011-04

  • Patients must have a life expectancy of at least 6 weeks

  • Lansky (=< 16 years) or Karnofsky (> 16 years) score of at least 50

  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment

  • Patients must not have received the therapies indicated below for the specified time period prior to the first day of administration of protocol therapy on this study

    • Myelosuppressive chemotherapy: must have received last dose at least 2 weeks prior to protocol therapy; this includes cytotoxic agents given on a low dose metronomic regimen
    • Biologic (anti-neoplastic agent) (includes retinoids): must have received last dose at least 7 days prior to protocol therapy
    • Monoclonal antibodies: must have received last dose at least 7 days or 3 half-lives, whichever is longer, prior to protocol therapy
  • Radiation:

    • Patients must not have received radiation (small port) for a minimum of two weeks prior to protocol therapy
    • Except for patients with a history of progressive disease, patients whose only site(s) of disease have been radiated are eligible if at least one lesion meets at least one of the criteria listed in sites of disease above
    • A minimum of 12 weeks prior to start of protocol therapy is required following large field radiation therapy (i.e. total body irradiation, craniospinal, whole abdominal, total lung, > 50% marrow space)
    • A minimum of 6 weeks must have elapsed prior to start of protocol therapy for other substantial bone marrow radiation
  • Stem Cell Transplant (SCT):

    • Patients are eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)
    • Patients are not eligible post allogeneic stem cell transplant
    • Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as 131 iodine [I]-MIBG) are eligible at any time as long as they meet the other criteria for eligibility
  • A minimum of 6 weeks must have elapsed after 131I-MIBG therapy prior to start of protocol therapy

  • Prior anti-disialoganglioside (GD2) antibody, isotretinoin, or lenalidomide therapy:

    • Patients who have received prior anti-GD2 antibody therapy are eligible if they did not have tumor relapse/progression while receiving this therapy
    • Patients who have received either isotretinoin or lenalidomide are eligible, but not if they have received the two agents concomitantly
  • All cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days prior to protocol therapy

  • Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study

  • Absolute phagocyte count (APC = neutrophils and monocytes): >= 1000/mm^3

  • Absolute neutrophil count: >= 750/mm^3

  • Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)

  • Hemoglobin >= 8.0 (may transfuse)

  • Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria; patients with marrow disease are not evaluable for hematologic toxicity

  • Age-adjusted serum creatinine =< 1.5 x normal for age or creatinine clearance or glomerular filtration rate (GFR) >= 60 cc/min/1.73 m^2

    • Age 1 month to < 6 months: 0.4 mg/dL for males and 0.4 mg/dL for females
    • Age 6 months to < 1 year: 0.5 mg/dL for males and 0.5 mg/dL for females
    • Age 1 to < 2 years: 0.6 mg/dL for males and 0.6 mg/dL for females
    • Age 2 to < 6 years: 0.8 mg/dL for males and 0.8 mg/dL for females
    • Age 6 to < 10 years: 1.0 mg/dL for males and 1.0 mg/dL for females
    • Age 10 to < 13 years: 1.2 mg/dL for males and 1.2 mg/dL for females
    • Age 13 to < 16 years: 1.5 mg/dL for males and 1.4 mg/dL for females
    • Age >= 16 years: 1.7 mg/dL for males and 1.4 mg/dL for females
  • =< grade 2 hematuria (criteria applicable only for dose levels that include isotretinoin) and =< grade 2 proteinuria

  • Total bilirubin =< 1.5 x upper limit of normal for age

  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3 x upper limit of normal (note that for ALT, the upper limit of normal is defined as 45 U/L)

  • Sinusoidal obstruction syndrome (SOS) if present, must be stable or improving clinically

  • Cardiac function:

    • Normal ejection fraction (>= 55%) documented by either echocardiogram or radionuclide multi gated acquisition scan (MUGA) evaluation; OR
    • Normal fractional shortening (>= 27%) documented by echocardiogram
  • No dyspnea at rest

  • Serum triglyceride =< 300 mg/dL (applicable only for dose levels that include isotretinoin) (note that a non-fasting triglyceride value could be obtained, if this is > 300 mg/dL then a fasting triglyceride should be obtained and patient will be eligible if the fasting level is =< 300 mg/dL)

  • =< grade 2 hypercalcemia (applicable only for dose levels that include cis retinoic acid [RA])

  • Skin toxicity =< grade 1

  • All post-menarchal females must have a negative beta-human chorionic gonadotropin (HCG); males and females of reproductive age and childbearing potential must use effective contraception for the duration of their participation; females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days and again within 24 hours prior to prescribing lenalidomide for cycle 1 and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy

  • Patients with other ongoing serious medical issues must be approved by the study chair prior to registration

Exclusion Criteria:

  • Quantitative serum b-HCG must be negative in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; pregnant or breast-feeding women will not be entered on this study
  • Breast feeding women are not eligible
  • Patients who have an active or uncontrolled infection are excluded
  • Patients with a paraben allergy cannot take isotretinoin preparations containing this compound (i.e. Accutane, Sotret) but are eligible if they can take an alternate preparation without paraben; (applicable only for entry onto dose levels receiving isotretinoin)
  • Patients with a history of venous or arterial thrombosis personally before the age of 40 years unless associated with a central line
  • Patients with a history of prior central nervous system (CNS) metastases or skull lesions with intracranial extension will be required to have a head computed tomography (CT) or magnetic resonance imaging (MRI) at study entry demonstrating no active CNS metastases; patients with skull metastases with associated intracranial soft tissue masses will remain eligible
  • Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be opened
  • Patient declines participation in NANT 2004-05; unless the institution has been granted special exemption from mandatory enrollment on NANT 2004-05 by the NANT Operations Center

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (lenalidomide, dinutuximab, isotretinoin)

Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given PO

其他名称:
  • CC-5013
  • 来那度胺
  • CC5013
  • 疾控中心 501
  • CC 5013

Correlative studies

Given IV

其他名称:
  • Ch14.18
  • 卡尔兹巴
  • 14.18UTC
  • 摩押 Ch14.18
  • 单克隆抗体 Ch14.18
  • 优妥昔单抗
  • Dinutuximab Beta

Given PO

其他名称:
  • 大赦
  • 肉桂烷
  • 克拉拉维斯
  • 索特雷
  • 13-顺视黄酸
  • 13-顺式视黄酸
  • 13-顺式维生素A酸
  • 13-cRA
  • 吸收剂
  • 准确的
  • 维甲酸
  • 顺维甲酸
  • 异维甲酸
  • 益生菌
  • 异曲霉素
  • 妙立山
  • 新维生素A
  • 新维生素A酸
  • 奥拉坦
  • 罗 4-3780
  • Ro-4-3780
  • 罗库坦
  • 泽纳坦

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum tolerated dose defined as the highest dose level tested at which 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) criteria, version 4.0
大体时间:Up to 28 days

All toxicities observed will be summarized in terms of type (organ affected or laboratory determination), severity (by NCI CTCAE), and attribution. Tables will be created to summarize these toxicities and side effects by dose level and by course as well as with Kaplan-Meier plots (i.e. time to first delay or dose reduction) in order to assess the tolerability of the regime over multiple courses.

Up to 28 days
Recommended phase II dose
大体时间:Up to 28 days

Determination of the recommended phase II dose of lenalidomide will include consideration of obtaining median peak plasma lenalidomide levels of 5-10 uM (based on laboratory modeling of this regimen in neuroblastoma), acceptable clinical toxicity, and laboratory evidence of an augmentation in immune function.

Up to 28 days

次要结果测量

结果测量
措施说明
大体时间
Overall survival
大体时间:From start of lenalidomide until death for any reason or date that patient was last known to be alive if the patient is still alive, assessed up to 3 years

Will be summarized with Kaplan-Meier plots.

From start of lenalidomide until death for any reason or date that patient was last known to be alive if the patient is still alive, assessed up to 3 years
Event-free survival
大体时间:From the start of treatment with lenalidomide until progression, clinical deterioration mandating that the patient terminate treatment or death due to any cause, whichever occurs first, assessed up to 3 years

Will be summarized with Kaplan-Meier plots.

From the start of treatment with lenalidomide until progression, clinical deterioration mandating that the patient terminate treatment or death due to any cause, whichever occurs first, assessed up to 3 years
Changes in the levels of T cells, natural killer (NK) cells, monocytes, cytokines, and chemokines
大体时间:Baseline to up to 28 days

These levels and the changes relative to baseline will be summarized by dose level by simple summary statistics: means (possibly after transformation) or medians, ranges, and standard deviations (if numbers and distribution permit). Scatterplots will be used to explore possible associations between the dose and day and toxicity experienced (as reflected in the maximum grade of toxicity experienced, infections or platelet recovery).

Baseline to up to 28 days
Changes in levels of HACA (or other genotype) and tumor response
大体时间:Baseline to up to 3 years

These levels and the changes relative to baseline will be summarized by dose level by simple summary statistics: means (possibly after transformation) or medians, ranges, and standard deviations (if numbers and distribution permit). Scatterplots will be used to explore possible associations between the dose and day and toxicity experienced (as reflected in the maximum grade of toxicity experienced, infections or platelet recovery).

Baseline to up to 3 years
Pharmacokinetic determinations of lenalidomide
大体时间:Baseline, at 60 and 90 minutes, at 2, 6, 24 hours and days 7 and 22 after last dose of lenalidomide in course 1

These will be summarized by dose level with simple summary statistics: means (possibly after transformation) or medians, ranges, and standard deviations (if numbers and distribution permit). Scatterplots will be used to explore possible associations between the dose and estimates of the pharmacokinetic parameters, and between the pharmacokinetic determinations and toxicity experienced (as reflected in the maximum grade of toxicity experienced or in clinical measurements).

Baseline, at 60 and 90 minutes, at 2, 6, 24 hours and days 7 and 22 after last dose of lenalidomide in course 1
Changes in TaqMan low density array (TLDA) scores
大体时间:Baseline to up to 3 years

Standard descriptive summaries as well as scatterplots will be used. The association between the changes in TLDA scores and overall tumor response will also be summarized graphically and quantitatively. Changes (from baseline) in the TLDA scores over the course of treatment will be plotted and summarized by dose level and course.

Baseline to up to 3 years
Overall response
大体时间:Up to 3 years

The association between the changes in TLDA scores and overall tumor response will be summarized graphically and quantitatively.

Up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Araz Marachelian、New Approaches to Neuroblastoma Treatment (NANT)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2013年2月4日

初级完成 (实际的)

2018年9月14日

研究完成 (估计的)

2027年3月3日

研究注册日期

首次提交

2012年10月18日

首先提交符合 QC 标准的

2012年10月18日

首次发布 (估计的)

2012年10月22日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅